Enver Akalin, MD, earned his medical degree at Ege University School of Medicine in Izmir, Turkey. He completed a research fellowship in the Renal Division at Brigham and Woman’s Hospital, Harvard Medical School, followed by a clinical fellowship in the Renal Division at Boston University School of Medicine. Dr. Akalin completed his residency in Internal Medicine as well as a clinical transplant nephrology fellowship in the Renal Division at Emory University School of Medicine, Atlanta.

After completing his fellowship, Dr. Akalin joined the Mount Sinai School of Medicine as a faculty in 2000 and served as the Medical Director of the Kidney and Pancreas Transplantation Program until January 2009. He is currently the Medical Director of the Kidney Transplantation Program at Montefiore Medical Center /Albert Einstein College of Medicine, Bronx, NY and Professor of Medicine and Surgery.

Dr. Akalin’s main research interest is understanding the mechanisms of allograft injury using microarrays and novel biomarkers. He is the first investigator who applied microarray technology in kidney transplant recipients which was published in 2001. Dr. Akalin received Young Investigator Travel Award of the American Society of Transplant Physicians twice and received American Society of Transplant Physicians Council’s Faculty Grant in 2002 to continue his research related to mechanisms of chronic allograft injury. He has had involved in multiple NIH studies and has active multiple RO1 grants. He involved in more than 25 multicenter clinical trials as a site principal investigator. He has authored or co-authored more than 135 original scientific articles, review articles and book chapters. He had served on the Editorial Board of the Clinical Journal of The American Society of Nephrology and Transplantation. He is currently the Chief Section Editor of Frontiers in Transplantation. Dr. Akalin chaired the American Society of Transplantation, Transplantation and Immunology Research Network, Clinical Science Grant Review Committee.

Dr. Akalin other interest is education of nephrology and transplant nephrology fellows. He started transplant nephrology fellowship program at Mount Sinai Medical Center in 2006 and at Montefiore Medical Center/Albert Einstein College of Medicine in 2011 and was the Transplant nephrology fellowship Director. He has served at Transplant Nephrology Fellowship Accreditation Committee for more than 10 years and chaired the Committee last 2 years. Later, he has served and chaired the governing board of Transplant Nephrology Fellowship Training Accreditation Programs. Dr. Akalin has served as Abstract Review Committee Chairman/co-Chairman/Reviewer at American Transplant Congress, World Transplant Congress, The Transplant Society Congress and Annual American Society of Nephrology Meetings. He currently serves at Education Committee of the Transplantation Society and Medical Directors Task Force of American Society of Transplantation. He has served at Clinical Trials Committee and chaired the Fellow of American Society of Transplantation Committee.

Dr. Akalin served at the New York Society of Nephrology as Academic Program Chairman, Secretary/Treasurer, vice president and president between 2013 and 2017.

Dr Akalin has involved at Banff Allograft Pathology Meetings and served at Molecular Diagnostic group.

Dr. Akalin is currently the fellow of American Society of Nephrology (FASN) and American Society of Transplantation (FAST).

1. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcomes. Clin J Am Soc Nephrol 2011; 6 : 922-936
2. Marfo K, Ling M, Bao Y, Calder B, Ye B, Greenstein S, Chapochnick-Friedman J, Glicklich D, de Boccardo G, Kinkhabwala M, and Akalin E. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly-sensitized patients at the top of the waiting list. (Transplantation 2012; 94 : 345-351)
3. Ling M, Masiakos P, Ibrahim A, Lindower J, Marfo K, Glicklich D, de Boccardo G, Greenstein S, Chapochnick-Friedmann J, Kinkhabwala M, and Akalin E. The prevalence and significance of HLA-Cw and HLA-DP antibodies in sensitized patients on the kidney transplant waiting list. (Human Immunology 2012; 73 : 879-883)
4. Nicole Hayde, Yi Bao, James Pullman, Bin Ye, Brent R. Calder, Monica Chung, DanielSchwartz, Ahmed Alansari, Graciela de Boccardo, Min Ling and Enver Akalin.The clinical and molecular significance of C4d staining patterns in renal allografts (Transplantation 2013; 95(4): 580-588).
5. Nicole Hayde, Yi Bao, James Pullman, Bin Ye, R. Brent Calder, Monica Chung, Daniel Schwartz, Michelle Lubetzky, Maria Ajaimy, Graciela de Boccardo and Enver Akalin. The clinical and genomic significance of donor-specific antibody (DSA) positive/C4d negative and DSA negative/C4d negative transplant glomerulopathy. (Clin J Am Soc of Nephrol 2013; 8: 2141-2148).
6. Nicole Hayde, Pilib Ó Broin, Yi Bao, Graciela de Boccardo, Michelle Lubetzky, Maria Ajaimy, James Pullman, Adriana Colavai, Aaron Golden, and Enver Akalin. Increased rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. Kidney International 2014; 86(3) : 600-609
7. Michelle Lubetzky, Yi Bao, Pilib Ó Broin, Kwaku Marfo, Maria Ajaimy, Aws Aljanabi, Graciela de Boccardo, Aaron Golden, and Enver Akalin. Genomics of BK viremia in kidney transplant recipients. (Transplantation 2014; 97: 451-456)
8. Pre-transplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-HLA antibodies. Kwaku Marfo, Maria Ajaimy, Adriana Colovai, Liise Kayler, Stuart Greenstein, Michelle Lubetzky, Anjali Gupta, Layla Kamal, Graciela de Boccardo, Peter Masiakos, Milan Kinkhabwala, and Enver Akalin. Transplantation 2014; 98: 1082-1088.
9. Layla Kamal, Pilib Ó Broin, Yi Bao, Maria Ajaimy, Michelle Lubetzky, Anjali Gupta, Graciela de Boccardo, James Pullman, Aaron Golden, and Enver Akalin. Clinical, histological, and molecular markers associated with allograft loss in transplant glomerulopathy patients. Transplantation 2015, 99(9); 1912-1918
10. Anjali Gupta, Pilib Ó Broin, Yi Bao, James Pullman, Layla Kamal, Maria Ajaimy, Michelle Lubetzky, Adriana Colovai, Daniel Schwartz, Graciela de Boccardo, Aaron Golden and Enver Akalin. Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney International 2016; 89: 217-225
11. Sumeyye Calp-Inal, Maria Ajaimy, Michal L. Melamed, Christina Savchik, Peter Masiakos, Adriana Colovai and Enver Akalin. The prevalence and clinical significance of C1q binding donor-specific anti-HLA antibodies early and late after kidney transplantation. Kidney International 2016; 89: 209-21
12. Ajaimy M, Lubetzky M, Jones T, Kamal L, Colovai A, de Boccardo G, Akalin E. Pregnancy in sensitized kidney transplant recipients: a single center experience. Clinical Transplantation 2016; 30(7): 791-795
13. Michelle Lubetzky, Soohwan Chun, Andrew Joelson, Maria Coco, Layla Kamal, Maria Ajaimy, Paul Gaglio, Enver Akalin and Graciela Deboccardo. Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients with Directly Acting Antiviral Agents. Transplantation 2017; 101: 1704-1710.
14. A Loupy, M Haas, K Solez, L Racusen, D Glotz, D Seron, B Nankivell, R B Colvin, M. Afrouzian, E. Akalin, N. Alachkar, S. Bagnasco, J. Becker, L. Cornell, C Drachenberg, D Dragun, I. Gibson, E S Kraus, C. Lefaucheur, H. Liapis, T Muthukumar, V. Nickeleit, B. Orandi, M Rabant, P. Randhawa, E Reed C. Roufosse, S. Sehan, B. Sis, S. Singh, C. Schinstock, A Tambur, A Zeevi, M. Mengel. The Banff 2015 Kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transpl 2017; 17: 28-41
15. Colovai AI, Ajaimy M, Kamal LG, Masiakos P, Chan S, Savchik C, Lubetzky M, de Boccardo G, Courson A, Chokechanachaisakul A, Graham J, Greenstein S, Kinkhabwala M, Rocca J, Akalin E. Increased Access to Transplantation of Highly Sensitized Patients Under the New Kidney Allocation System. A Single Center Experience. Human Immunol 2017; 78: 257-262.
16. Philip F. Halloran, Enver Akalin, Olivier Aubert, Georg Bohmig, Daniel Brennan, Jonathan Bromberg, Gunilla Einecke, Farsad Eskandary, Clement Gosset, Gaurav Gupta, Carmen Lefaucheur, Andrew Malone, Daniel Seron, Joana Sellares, Matt Weir, and Alexandre Loupy. Real time central assessment of kidney transplant indication biopsies by microarrays: The INTERCOMEX Study. Am J Transpl 2017, 17 : 2851-2862
17. Efficacy DNA methylation on progression to interstitial fibrosis and tubular atrophy renal allograft biopsies. A multi-omics approach. Bontha SV, Maluf DG, Archer KJ, Dumur CI, Dozmorov MG, King AL, Akalin E, Mueller TF, Gallon L, Mas VR. Am J Transplant. 2017
18. The Banff 2017 Kidney Meeting Report: Revised Diagnostic Criteria for Chronic Active T Cell-Mediated Rejection, Antibody-Mediated Rejection, and Prospects for Integrative Endpoints for Next-Generation Clinical Trials. M Haas, A Loupy, C Lefaucheur, C Roufosse, D Glotz, D Seron, B J Nankivell, P F Halloran, R B Colvin, E. Akalin, N Alachkar, S Bagnasco, Y Bouatou, J U Becker, L Cornell, JP Duong van Huyen, I Gibson, R Mannon, M Naesens, V Nickeleit, P Nickerson, D L Segev, H K Singh, M Stegall, P Randhawa, L Racusen, K Solez, M Mengel. Am J Transplant. 2018 Feb;18(2):293-307
19. Deceased-donor acute kidney injury is not associated with kidney allograft failure. Hall  IE, Akalin E, Bromberg JS, Doshi MD, Greene T, Harhay MN, Jia Y, Mansour SG, Mohan S, Muthukumar T, Reese PP, Schröppel B, Singh P, Thiessen-Philbrook HR, Weng FL, Parikh CR. Kidney Int. 2019 Jan;95(1):199-209
20. Molecular Signatures and Clinical Outcomes of Transplant Glomerulopathy Stratified by Microvascular Inflammation and Donor-Specific Antibody. Lubetzky M, Hayde N, Ó Broin P, Ajaimy M, Bao Y, Mohammed O, Schwartz D, Pullman J, Akalin E. Clin Transplant. 2018 Dec 22:e13469
21. Peri-transplant eculizumab does not prevent delayed kidney function in deceased donor kidney transplant recipients: results of two randomized controlled pilot trials. Schröppel B, Akalin E, Baweja M, Bloom RD, Florman S, Goldstein M, Haydel B, Hricik DE, Kulkarni S, Levine M, Mehrotra A, Patel A, Poggio ED, Ratner L, Shapiro R, Heeger PS. Am J Transplant. 2019 Aug    
22. Assessment of Organ Quality in Kidney Transplantation by Molecular Analysis and Why It May Not Have Been Achieved, Yet. von Moos S, Akalin E, Mas V, Mueller TF. Front Immunol. 2020 May 12;11:833
23. COVID-19 and Solid Organ Transplantation: A Review Article. Azzi Y, Bartash R, Scalea J,  Loarte-Campos P, Akalin E.Transplantation. 2021 Jan 1;105(1):37-55

24. COVID-19 and kidney transplantation. Akalin E, Azzi Y, Bartash R, Seethamraju H,

    Parides M, Hemmige V, Ross M, Forest S, Goldstein YD, Ajaimy M, Liriano-

    Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M. N Engl J Med. 2020 Apr 24

25. A CRISPR-based Assay for the Detection of Opportunistic Infections Post-Transplantation and for the Monitoring of Transplant Rejection.  Kaminski MM,   Alcantar MA, Lape IT, Greensmith R,  Huske AC, Valeri JA, Marty FM, Klämbt  V, Azzi J, Akalin E, Riella LV, Collins JJ. Nat  Biomed Eng. 2020 Apr 13

26. Glycemic management and clinical outcomes in underserved minority kidney transplant recipients with type 2 and posttransplantation diabetes: A single-center retrospective study. Aleksic S, Eisenberg R, Tsomos E, Zahedpour Anaraki S, Japp E, Upadhyay L, Mowrey WB, Akalin E, Zonszein J. Diabetes Res Clin Pract. 2020 May 20;165:108221

27. Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation - Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Mengel M, Loupy A, Haas M, Roufosse C, Naesens M, Akalin E, Clahsen-van Groningen MC, J Dagobert, Demetris AJ, Duong van Huyen JP, Gueguen J, Issa F, Robin B, Rosales I, Von der Thüsen JH, Sanchez-Fueyo A, Smith RN, Wood K, Adam B, Colvin RB. Am J Transplant. 2020 May 19.

28. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell LD, Clahsen-van Groningen MC, Demetris AJ, Dragun D, Duong van Huyen JP, Farris AB, Fogo AB, Gibson IW, Glotz D, Gueguen J, Kikic Z, Kozakowski N, Kraus E, Lefaucheur C, Liapis H, Mannon RB,Montgomery RA, Nankivell BJ, Nickeleit V, Nickerson P, Rabant M, Racusen L,Randhawa P, Robin B, Rosales IA, Sapir-Pichhadze R, Schinstock CA, Seron D,Singh HK, Smith RN, Stegall MD, Zeevi A, Solez K, Colvin RB, Mengel M. Am J Transplant. 2020 May

29. Peri-transplant eculizumab does not prevent delayed kidney function in deceased donor kidney transplant recipients: results of two randomized controlled pilot trials. Schröppel B, Akalin E, Baweja M, Bloom RD, Florman S, Goldstein M, Haydel B, Hricik DE, Kulkarni S, Levine M, Mehrotra A, Patel A, Poggio ED, Ratner L, Shapiro R, Heeger PS. Am J Transplant. 2020 Feb;20(2):564-572